Apixaban Dosing and Management
Standard Dosing
For atrial fibrillation, the standard dose of apixaban is 5 mg twice daily, with dose reduction to 2.5 mg twice daily ONLY when patients meet at least 2 of 3 specific criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (≥133 μmol/L). 1, 2
Dose Reduction Criteria (Atrial Fibrillation)
The most critical prescribing error with apixaban is inappropriate dose reduction—occurring in up to 40% of prescriptions—which significantly increases thromboembolic risk 3. You must have TWO of the following three criteria present to justify the 2.5 mg twice daily dose 1, 4:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (≥133 μmol/L)
Having only ONE criterion does NOT justify dose reduction. This is where most prescribing errors occur—clinicians inappropriately reduce the dose based on a single factor like advanced age or mild renal impairment 3.
Renal Dosing Considerations
Unlike rivaroxaban, apixaban does NOT require routine dose reduction for moderate renal impairment (CrCl 30-50 mL/min) in atrial fibrillation 5. Only 25% of apixaban is renally excreted, compared to 33% for rivaroxaban and 80% for dabigatran 5.
For CrCl 30-50 mL/min: Continue 5 mg twice daily unless the patient meets 2 of the 3 dose-reduction criteria listed above 1, 5.
For CrCl 15-29 mL/min: Very limited trial data exists. The 2024 ESC guidelines provide no specific recommendation 1. The 2014 AHA/ACC/HRS guideline states "no recommendation" for this population 4.
For end-stage CKD on hemodialysis: Use 5 mg twice daily, reduced to 2.5 mg twice daily if age ≥80 years OR body weight ≤60 kg (note: only ONE criterion needed in dialysis patients) 4, 2.
VTE Treatment Dosing
For acute DVT/PE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily 2, 6. No dose reduction is recommended for renal impairment when treating acute VTE 4, 7.
For VTE prophylaxis after hip/knee replacement: 2.5 mg twice daily starting 12-24 hours post-operatively 6.
Drug Interactions
Strong CYP3A4 and P-glycoprotein Inhibitors
If the patient is on 5 mg twice daily AND you add a combined strong CYP3A4 and P-gp inhibitor (ketoconazole, itraconazole, ritonavir, clarithromycin), reduce to 2.5 mg twice daily 2, 8.
If already on 2.5 mg twice daily, AVOID apixaban entirely when adding these inhibitors 2.
Strong CYP3A4 and P-glycoprotein Inducers
Avoid concurrent use with rifampin, carbamazepine, phenytoin, or St. John's wort—these significantly reduce apixaban levels and efficacy 2, 8.
Antiplatelet Agents
Concurrent aspirin or P2Y12 inhibitors increase bleeding risk by at least 60% 8. In most patients with atrial fibrillation, antiplatelet agents should be discontinued when starting apixaban 1.
Contraindications
- Active pathological bleeding 9
- Severe hypersensitivity reaction to apixaban 9
- Prosthetic heart valves (apixaban not studied and not recommended) 1
- Moderate-to-severe mitral stenosis 1
Reversal Options
Andexanet Alfa (Preferred Specific Reversal Agent)
For life-threatening bleeding or urgent surgery in patients on apixaban, andexanet alfa is the FDA-approved specific reversal agent 10, 11.
Dosing:
- Low-dose regimen: 400 mg IV bolus at 30 mg/min, followed by 4 mg/min infusion for up to 120 minutes (for last apixaban dose <10 mg or taken >8 hours ago) 2
- High-dose regimen: 800 mg IV bolus at 30 mg/min, followed by 8 mg/min infusion for up to 120 minutes (for last apixaban dose ≥10 mg taken ≤8 hours ago) 2
In the ANNEXA-4 study, andexanet reduced anti-Xa activity by 93% with 80% achieving excellent/good hemostasis at 12 hours 10. However, thrombotic events occurred in 10% of patients 10.
Four-Factor Prothrombin Complex Concentrate (Alternative)
When andexanet is unavailable, use 4-factor PCC 2, 11. Dosing based on INR for warfarin reversal can be extrapolated: 25-50 units/kg depending on urgency 2.
Activated Charcoal
If apixaban was taken within 2 hours, activated charcoal may reduce absorption 11.
Peri-procedural Management
Pre-procedure Interruption
Timing depends on bleeding risk of the procedure and renal function 6:
For LOW bleeding risk procedures (CrCl >50 mL/min):
- Stop apixaban 24 hours (1 day) before procedure 6
For HIGH bleeding risk procedures:
- CrCl >50 mL/min: Stop 48 hours (2 days) before 6
- CrCl 30-50 mL/min: Stop 72 hours (3 days) before 6
- CrCl 15-29 mL/min: Stop 96 hours (4 days) before 6
For VERY HIGH bleeding risk (neurosurgery, neuraxial anesthesia):
- Stop 5 days before procedure regardless of renal function 6
- Consider measuring anti-Xa levels if available 6
Neuraxial Anesthesia Warning
Do NOT perform spinal/epidural anesthesia or deep nerve blocks if there is any possibility of residual apixaban concentration 6. This is particularly critical in elderly patients or those with renal impairment where drug clearance is prolonged 7.
Post-procedure Resumption
- Low-dose prophylaxis (LMWH or fondaparinux): Start 6 hours post-procedure 6
- Resume therapeutic apixaban: 24-72 hours post-procedure once hemostasis is secure 6
- If using bridging LMWH, give first therapeutic apixaban dose 12 hours after last prophylactic LMWH 6
Monitoring Requirements
No routine laboratory monitoring is required 1. However, specific situations warrant assessment:
When to Check Apixaban Levels (Anti-Xa Assay)
- Suspected non-adherence 7
- Peri-procedural planning in high-risk patients 7
- Extremes of body weight 7
- Severe renal impairment 7
- Suspected drug accumulation 7
Peak levels: 3-4 hours post-dose 2
Trough levels: Just before next dose 2
Renal Function Monitoring
Check creatinine clearance (Cockcroft-Gault formula):
- Before initiating apixaban 5, 1
- At least annually 5, 4
- During any intercurrent illness affecting volume status or renal function (gastroenteritis, influenza, post-surgery) 5
- When starting medications affecting renal function (ACE inhibitors, ARBs, NSAIDs) 5
Common Prescribing Pitfalls
Underdosing based on single criterion: The most common error—reducing to 2.5 mg twice daily with only ONE dose-reduction criterion present (e.g., age 82 but weight 75 kg and creatinine 1.2 mg/dL) 3, 12
Inappropriate dose reduction for moderate renal impairment alone: CrCl 30-50 mL/min does NOT automatically warrant dose reduction in atrial fibrillation 5
Dose reduction for acute VTE treatment: Never reduce apixaban dose for renal impairment when treating acute DVT/PE 7
"Blindly continuing home dose": Always reassess dose-reduction criteria at each transition of care 3
Premature discontinuation: Abrupt cessation increases stroke risk—ensure bridging plan if stopping 1